Desentum
Desentum is developing a new immunotherapy for the treatment of allergies – an allergy vaccine.
Funding rounds
10/2017, 9/2019, 1/2022, 1/2024
Valuation after latest round
€73 million
Springvest's ownership stake
6.8% (31 December 2025)
Sector
Life sciences
